GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Hikal Ltd

Hikal Ltd Reports Q2 FY27 Standalone Loss of Rs. 62 Million, Revenue Rs. 4,342 Million

RESULTS ◆ Monitor Closely MEDIUM RISK
📅 Filed on BSE: 03 Nov 2026, 02:30 PM IST  ·  BSE ID: f32536a7-52ff-4584-adf9-96698ab27ba0
View Original BSE Filing (PDF)
💡
In Simple Terms
Hikal Ltd recorded a Rs. 62 Million loss in the September 2026 quarter, with sales totaling Rs. 4,342 Million.
🤖 AI Summary
  • Hikal Ltd reported a standalone loss of Rs. 62 Million for the quarter ended September 30, 2026 (Q2 FY27).
  • Revenue from operations for Q2 FY27 stood at Rs. 4,342 Million, up from Rs. 4,028 Million in Q1 FY27.
  • For the half-year ended September 30, 2026, the standalone loss was Rs. 137 Million on revenue of Rs. 8,370 Million.
  • Pharmaceuticals segment revenue was Rs. 2,778 Million, and Crop Protection and Specialty Ingredients revenue was Rs. 1,564 Million in Q2 FY27.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Loss for the period (Q2 FY27 Standalone)
(62) Rs. In Million
Revenue from operations (Q2 FY27 Standalone)
4,342 Rs. In Million
Loss for the period (Half Year FY27 Standalone)
(137) Rs. In Million
Revenue from operations (Half Year FY27 Standalone)
8,370 Rs. In Million
Pharmaceuticals Segment Revenue (Q2 FY27 Standalone)
2,778 Rs. In Million
Crop protection and speciality ingredients Segment Revenue (Q2 FY27 Standalone)
1,564 Rs. In Million
🏢 How This Affects the Company
📈
Business Impact
The Pharmaceuticals segment's revenue increased to Rs. 2,778 Million in Q2 FY27 from Rs. 2,333 Million in Q1 FY27, while the Crop Protection segment revenue decreased to Rs. 1,564 Million from Rs. 1,695 Million.
💰
Financial Impact
The company's standalone loss for Q2 FY27 was Rs. 62 Million, an improvement from the Rs. 75 Million loss in Q1 FY27 and Rs. 347 Million loss in Q2 FY26. Total expenses for Q2 FY27 were Rs. 4,445 Million.
⚙️
Operational Impact
Revision/reassessment of pension and gratuity benefit assumptions led to a reduction in employee benefit obligations by Rs. 79 Million during the quarter and half year ended September 30, 2026.
⚠️
Risk Impact
A note highlighted ongoing uncertainty regarding investigations by statutory authorities for alleged environmental non-compliance, with no adjustments considered necessary in financial results at this stage.
👥 What This Means For Shareholders
✅
Action Required
Shareholders are not required to take any immediate action based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the reported standalone loss of Rs. 62 Million for Q2 FY27 and the half-year loss of Rs. 137 Million. Basic and Diluted EPS for Q2 FY27 were (0.50).
🔍
Management Signal
The management's report highlights ongoing efforts to manage employee benefit obligations and address environmental litigation, indicating focus on cost and risk management.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — check for sustained reduction in standalone losses.
Updates on the environmental law compliance case pending before the Supreme Court.
Details on the impact of the USFDA warning letter on Pharma Segment sales in subsequent quarters.
MEDIUM RISK Ongoing standalone losses and unresolved environmental litigation pose financial and regulatory risks.
💡 Investor Takeaway
Hikal Ltd reported a Q2 FY27 standalone loss of Rs. 62 Million on total income of Rs. 4,359 Million, improving from Q2 FY26's loss of Rs. 347 Million on total income of Rs. 3,204 Million. Half-year standalone loss stands at Rs. 137 Million.
⚖️ Strengths & Concerns

✅ Positives

  • Standalone loss for Q2 FY27 of Rs. 62 Million shows an improvement compared to the Rs. 347 Million loss in Q2 FY26.
  • Pharmaceuticals segment revenue increased to Rs. 2,778 Million in Q2 FY27 from Rs. 1,895 Million in Q2 FY26.

⚠️ Concerns

  • The company reported a standalone loss of Rs. 62 Million for Q2 FY27, following a Rs. 75 Million loss in Q1 FY27.
  • Total expenses for Q2 FY27 were Rs. 4,445 Million, exceeding total income of Rs. 4,359 Million.
📅 Company Track Record
Hikal Ltd reported a Q1 FY27 standalone net loss of Rs. 75 Million on revenue of Rs. 4,028 Million. In Q4 FY26, the company recorded a standalone net profit of Rs. 146 Million and recommended a final dividend of ₹ 0.40/share. A USFDA warning letter in August 2025 has impacted Pharma Segment sales.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Hikal Ltd's standalone net loss in Q2 FY27?
Hikal Ltd reported a standalone loss for the period of Rs. 62 Million for the quarter ended September 30, 2026 (Q2 FY27).
What was Hikal Ltd's revenue from operations in Q2 FY27?
Revenue from operations for Hikal Ltd in Q2 FY27 was Rs. 4,342 Million.
What were the revenues for Hikal Ltd's Pharmaceuticals and Crop Protection segments in Q2 FY27?
In Q2 FY27, the Pharmaceuticals segment generated Rs. 2,778 Million in revenue, and the Crop protection and speciality ingredients segment generated Rs. 1,564 Million.
What was the total standalone loss for Hikal Ltd for the half-year ended September 30, 2026?
Hikal Ltd's total standalone loss for the half-year ended September 30, 2026, was Rs. 137 Million.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses free when you sign up

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.

Live IPO, GMP and market updates on Telegram

IPO open and close dates, grey market premium moves, subscription figures, allotment and listing days, and the market updates worth knowing about, posted on the channel as they happen.

Join the channel